Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Massive investment and technological advances in the collection of extensive and longitudinal information on thousands of Alzheimer patients results in large amounts of data. These “big‐data” databases can potentially advance CNS research and drug development. However, although necessary, they are not sufficient, and we posit that they must be matched with analytical methods that go beyond retrospective data‐driven associations with various clinical phenotypes. Although these empirically derived associations can generate novel and useful hypotheses, they need to be organically integrated in a quantitative understanding of the pathology that can be actionable for drug discovery and development. We argue that mechanism‐based modeling and simulation approaches, where existing domain knowledge is formally integrated using complexity science and quantitative systems pharmacology can be combined with data‐driven analytics to generate predictive actionable knowledge for drug discovery programs, target validation, and optimization of clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“6% of the clinical trials of diseasemodifying treatments for AD have failed [4].”
BackgroundCost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484
Adaptive deep brain stimulation in advanced Parkinson disease.
Little, S., Pogosyan, A., Neal, S., Zavala, B., Zrinzo, L., Hariz, M., Foltynie, T., Limousin, P., Ashkan, K., FitzGerald, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23951 · Cited by 1,374 · cited 1×
“…the clinical observation from deep brain recordings in Parkinson’s disease patients that motor symptoms are not related to firing frequencies, but to complex oscillatory behavior of local field potentials [31] is an example of an unexpected emergent property that cannot be reduced to a single target.”
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“Trials have generally failed, but secondary analysis of a clinical trial in AD patients reported that APOE ε 2/ ε 2, APOE ε 2/ ε 3 carriers benefited, whereas APOE ε 2/ ε 4, APOE ε 3/ ε 4 and APOE ε 4/ ε 4 carriers did not [37].”
ResultIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236 · cited 1×
“Recent studies indeed document different aggregation dynamics [12], different formation and clearance in the human brain [13], different neuroprotective versus neurotoxic properties of the shorter versus longer amyloid peptides [14], and the complex nonlinear interaction of co-medications and…”
Peterson, M., & Riggs, M. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.20 · Cited by 77 · cited 1×
“Physiology-based pharmacokinetic modeling, which uses mechanism-based equations rather than empirical methods [23], is now part of the growing toolbox of the pharmaceutical industry and is increasingly being accepted by regulatory agencies [24,25].”
Background
Cited by
Concurrence of big data analytics and healthcare: a systematic review
Mehta, N., & Pandit, A. (2018) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2018.03.013 · Cited by 494
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459
Leveraging big data analytics in healthcare enhancement: trends, challenges and opportunities
Rehman, A., Naz, S., & Razzak, I. (2022) · Multimedia Systems · doi:10.1007/s00530-020-00736-8 · Cited by 264
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Hampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
Metadata
- Authors
- Geerts, H., Dacks, P. A., Devanarayan, V., Haas, M., Khachaturian, Z. S., Gordon, M. F., Maudsley, S., Romero, K., Stephenson, D., & (BHMI), B. H. M. I.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2016-05-27
- Volume
- 12
- Issue
- 9
- Pages
- 1014-1021
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2402500880
- Cited by
- 79
- References
- 11
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.